Learn About Lymphadenopathy and New Treatments for Lymphoproliferative Disorders

OSUWexnerbloglogo2014 Learn About Lymphadenopathy and New Treatments for Lymphoproliferative Disorders. Today on MedNet21, we are going to bring you up to date on the approach to lymphadenopathy and then tell you about some exciting new treatments for lymphoma that are changing the management of the disease. Our guests today are hematologist and Assistant Professor of Internal medicine, Dr. David Bond. And also Assistant Professor of Internal Medicine from the Division of Hematology, Dr. Yazeed Sawalha.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: review the mechanisms
of action and clinical data of (CAR) T cells and BiTEs in patients with relapsed/refractory B-cell non-Hodgkin lymphoma; highlight unique toxicities associated with CAR T cells and BiTEs: cytokines release syndrome and neurotoxicity; recognize the leading differential diagnosis considerations for a patient presenting with undifferentiated lymphadenopathy; and Differentiate diagnostic biopsy approaches including fine needle aspiration, core needle biopsy, and excisional lymph node biopsy.

You’ll also learn about the following:

  • New treatments for lymphoma
  • Cost and insurance coverage for CAR T-cells and bispecific T-cell engagers
  • What patients should expect during treatment
  • Stem cell transplant timing
  • Stem cell transplant versus bone marrow transplant

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Learn About New Treatments for Osteoporosis

OSUWexnerbloglogo2014 Learn About New Treatments for Osteoporosis. On this CME webcast, we’re going to bring you up to date on the latest recommendations for the management of osteoporosis and on the latest developments in pharmacologic treatment. Joining our moderator in the studio is endocrinologist and Associate Professor of Internal Medicine, Dr. Steven Ing. And endocrinologist and also Associate Professor of Internal Medicine, Dr. Laura Ryan.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DISCUSS 2017 ACP guidelines on osteoporosis; DISCUSS studies subsequent to guidelines; UNDERSTAND the latest data on therapy for postmenopausal osteoporosis using evidence based clinical studies; and IMPROVE comfort in deciding on initial therapy to choose for patients at high risk for fracture, then monitoring that choice over time.

You’ll also learn about the following:

  • New developments in osteoporosis treatment
  • Choosing a bisphosphonate
  • Calcium & vitamin D

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Learn the Latest on Hepatocellular Carcinoma Viewing CME Webcast

OSUWexnerbloglogo2014 Learn the Latest on Hepatocellular Carcinoma Viewing CME Webcast. Here in the United States, the incidence of hepatocellular carcinoma is rising. The way that we approach cancer of the liver has changed over the past 20 years and today on MedNet, we are going to bring you up to date on the epidemiology, screening, diagnosis, and treatment of hepatocellular carcinoma. Joining us today is hepatologist and Assistant Professor of Internal Medicine, Dr. Lanla F. Conteh.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: UNDERSTAND the epidemiology of hepatocellular carcinoma in the United States; and RECOGNIZE which patients should be screened for hepatocellular carcinoma.

You’ll also learn about the following:

  • The rising incidence of hepatocellular carcinoma
  • New directions in treatment of hepatocellular carcinoma
  • Imaging test of choice in suspected hepatocellular carcinoma
  • How to biopsy suspected hepatocellular carcinoma
  • Viral hepatitis risk factors for hepatocellular carcinoma
  • Fibrolamellar hepatocellular carcinoma

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Learn About New Therapies for Type 2 Diabetes

OSUWexnerbloglogo2014 Learn About New Therapies for Type 2 Diabetes. 25 years ago, the management of type II diabetes was easy. You started a patient on a sulfonylurea and then if their glucose level didn’t improve, you added in NPH insulin. But things have changed. And today, we have better and safer medications to treat diabetes. Which is a good thing because the prevalence of diabetes over the past 25 years has grown enormously and we really needed new treatments to fight against this public health threat. But with new treatments can come confusion about which to use in different clinical situations. Joining our moderator on this CME webcast, to update us on the management of type 2 diabetes is endocrinologist and Assistant Professor of Internal Medicine from the Ohio State University, Dr. Joshua Joseph.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DESCRIBE the role of new medical therapies in hypoglycemia; and DESCRIBE the role of new medical therapies in cardiovascular disease.

You’ll also learn about the following:

  • New directions in the treatment of type 2 diabetes
  • Hemoglobin A1C targets
  • Treatment of type 2 diabetes when medication cost is a consideration
  • New glucose monitoring technologies

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

CME Webcast Discusses New Therapies for Lung Cancer

OSUWexnerbloglogo2014 CME Webcast Discusses New Therapies for Lung Cancer. On this CME webcast, we’re going to update you on the medical management of lung cancer and focus on non-small cell lung cancer. Joining our moderator in the studio is medical oncologist at the James Cancer Hospital and Professor of Internal Medicine from the Ohio State University, Dr. David Carbone.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: Review some of the latest practice-changing findings in the management of lung cancer; and Understand the basic principles of workup and initial lung cancer management decisions.

You’ll also learn about the following:

  • Classifying non-small cell lung cancer
  • Common side effects of driver-targeted therapies
  • What the primary care physician needs to know about co-managing patients taking driver-targeted therapy

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.